Nucleic Acids Research, 2000, Vol. 28, No. 10 2141-2152
© 2000 Oxford University Press
Methylation mosaicism of 5'-(CGG)n-3' repeats in fragile X, premutation and normal individuals
Institute of Genetics, University of Cologne, D-50931 Köln, Germany, 1Institut für Humangenetik, Universität Düsseldorf, D-40225 Düsseldorf, Germany and 2Department of Child and Adolescent Psychiatry, University of Cologne, D-50931 Köln, Germany
Fragile X syndrome (FRAXA) is characterized at the molecular level by an expansion of a naturally occurring 5'-(CGG)n-3' repeat in the promoter and 5'-untranslated region (5'-UTR) of the fragile X mental retardation (FMR1) gene on human chromosome Xq27.3. When expanded, this region is usually hypermethylated. Inactivation of the FMR1 promoter and absence of the FMR1 protein are the likely cause of the syndrome. By using the bisulfite protocol of the genomic sequencing method, we have determined the methylation patterns in this region on single chromosomes of healthy individuals and of selected premutation carriers and FRAXA patients. In control experiments with unmethylated or M-SssI-premethylated DNAs, this protocol has been ascertained to reliably detect all cytidines or 5-methylcytidines as unmethylated or methylated nucleotides, respectively. Analyses of the DNA from FRAXA patients reveal considerable variability in the lengths of the 5'-(CGG)n-3' repeats and in the levels of methylation in the repeat and the 5'-UTR. In one patient (OEl) with high repeat length heterogeneity (n = 15 to >200), shorter repeats (n = 20–80) were methylated or unmethylated, longer repeats (n = 100–150) were often completely methylated, but one repeat with n = 160 proved to be completely unmethylated. This type of methylation mosaicism was observed in several FRAXA patients. In healthy females, methylated 5'-CG-3' sequences were found in some repeats and 5'-UTRs, as expected for the sequences from one of the X chromosomes. The natural FMR1 promoter is methylation sensitive, as demonstrated by the loss of activity in transfection experiments using the unmethylated or M-SssI-premethylated FMR1 promoter fused to the luciferase gene as an activity indicator.
* To whom correspondence should be addressed. Tel: +49 221 470 2386; Fax: +49 221 470 5163; Email: doerfler@scan.genetik.uni-koeln.de Present address: Michael Zeschnigk, Institut für Humangenetik, Universitätsklinikum Essen, D-45122 Essen, Germany
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Dahl, K. Gronskov, L. A. Larsen, P. Guldberg, and K. Brondum-Nielsen A Homogeneous Assay for Analysis of FMR1 Promoter Methylation in Patients with Fragile X Syndrome Clin. Chem., April 1, 2007; 53(4): 790 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Gray, J. Gerhardt, W. Doerfler, L. E. Small, and E. Fanning An Origin of DNA Replication in the Promoter Region of the Human Fragile X Mental Retardation (FMR1) Gene Mol. Cell. Biol., January 15, 2007; 27(2): 426 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. T. Smith, B. Coffee, and D. Reines Occupancy and synergistic activation of the FMR1 promoter by Nrf-1 and Sp1 in vivo Hum. Mol. Genet., August 1, 2004; 13(15): 1611 - 1621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nichol and a. C. E. Pearson CpG Methylation Modifies the Genetic Stability of Cloned Repeat Sequences Genome Res., August 1, 2002; 12(8): 1246 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pietrobono, M. G. Pomponi, E. Tabolacci, B. Oostra, P. Chiurazzi, and G. Neri Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine Nucleic Acids Res., July 15, 2002; 30(14): 3278 - 3285. [Abstract] [Full Text] [PDF]
|
|